1
|
Prudhomme T, Andras I, Boissier R, Campi R, Hevia V, Territo A, Kidney Transplant Group EAOUYAU. Endovesical Bacillus Calmette-Guérin for Nonmuscle Invasive Bladder Cancer in Kidney Transplant Recipients: Is It Safe and Efficacious? EXP CLIN TRANSPLANT 2022; 20:789-791. [DOI: 10.6002/ect.2022.0154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
2
|
Boissier R, Hidalgo R, Rodríguez Faba O, Territo A, Subiela JD, Huguet J, Sánchez-Puy A, Gallioli A, Vanacore D, Mercade A, Martinez C, Palou J, Guirado L, Breda A. History of urological malignancies before kidney transplantation, oncological outcome on the long term. Actas Urol Esp 2021; 45:623-634. [PMID: 34764048 DOI: 10.1016/j.acuroe.2020.10.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Accepted: 10/05/2020] [Indexed: 10/19/2022]
Abstract
INTRODUCTION We aimed to report the oncological outcomes of ESRD patients with histories of urological malignancies who were subsequently submitted to kidney transplantation (KT). MATERIAL AND METHOD Retrospective study lead in the Puigvert Foundation (Barcelona) registry of 1,200 KT performed from 1988 to 2018. Eighty-five urological malignancies that were treated before KT in 81 patients were identified: 15 (18%) prostate cancers, 49 (58%) RCC, 19 (22%) urothelial carcinomas and 2 (2%) testicular cancers. Baseline characteristics, cancer staging, treatment and follow-up were registered as well as the chronology of the start of dialysis, inscription on the waiting list and kidney transplantation. Endpoints included were cancer recurrence, metastatic progression, cancer-specific death and overall survival. RESULTS In a median follow-up of 13.1 years (2.2-32), 16/85 (19%) cancer recurrences were reported, with 3 (4%) who progressed to metastasis and died of cancer. Median overall survival after cancer treatment was 25.3 years and cancer-specific survival was 95% at 25 years. Median time from cancer treatment to kidney transplantation was 4.8 years: 3.7 years in prostate cancer, 3.9 years in RCC and 8.8 years in bladder cancer. The median time from start of dialysis to kidney transplantation was 1.8 years in patients with histories of urological malignancy versus 0.5 year in the total cohort of 1,200 renal transplanted over the same period. CONCLUSIONS Well-selected patients with histories of urological malignancies greatly benefit from kidney transplantation with infrequent and late cancer recurrence. Waiting time could be optimized in low-risk prostate cancer and RCC, but more robust data are needed.
Collapse
Affiliation(s)
- R Boissier
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain.
| | - R Hidalgo
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - O Rodríguez Faba
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - A Territo
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - J D Subiela
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - J Huguet
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - A Sánchez-Puy
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - A Gallioli
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - D Vanacore
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - A Mercade
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - C Martinez
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - J Palou
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - L Guirado
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| | - A Breda
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Spain
| |
Collapse
|
3
|
Boissier R, Hidalgo R, Rodríguez Faba O, Territo A, Subiela JD, Huguet J, Sánchez-Puy A, Gallioli A, Vanacore D, Mercade A, Martinez C, Palou J, Guirado L, Breda A. History of urological malignancies before kidney transplantation, oncological outcome on the long term. Actas Urol Esp 2021; 45:S0210-4806(21)00104-2. [PMID: 34172308 DOI: 10.1016/j.acuro.2020.10.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Accepted: 10/05/2020] [Indexed: 11/23/2022]
Abstract
INTRODUCTION We aimed to report the oncological outcomes of ESRD patients with histories of urological malignancies who were subsequently submitted to kidney transplantation (KT). MATERIAL AND METHOD Retrospective study lead in the Puigvert Foundation (Barcelona) registry of 1,200 KT performed from 1988 to 2018. Eighty-five urological malignancies that were treated before KT in 81 patients were identified: 15 (18%) prostate cancers, 49 (58%) RCC, 19 (22%) urothelial carcinomas and 2 (2%) testicular cancers. Baseline characteristics, cancer staging, treatment and follow-up were registered as well as the chronology of the start of dialysis, inscription on the waiting list and kidney transplantation. Endpoints included were cancer recurrence, metastatic progression, cancer-specific death and overall survival. RESULTS In a median follow-up of 13.1 years (2.2-32), 16/85 (19%) cancer recurrences were reported, with 3 (4%) who progressed to metastasis and died of cancer. Median overall survival after cancer treatment was 25.3 years and cancer-specific survival was 95% at 25 years. Median time from cancer treatment to kidney transplantation was 4.8 years: 3.7 years in prostate cancer, 3.9 years in RCC and 8.8 years in bladder cancer. The median time from start of dialysis to kidney transplantation was 1.8 years in patients with histories of urological malignancy versus 0.5 year in the total cohort of 1,200 renal transplanted over the same period. CONCLUSIONS Well-selected patients with histories of urological malignancies greatly benefit from kidney transplantation with infrequent and late cancer recurrence. Waiting time could be optimized in low-risk prostate cancer and RCC, but more robust data are needed.
Collapse
Affiliation(s)
- R Boissier
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España.
| | - R Hidalgo
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - O Rodríguez Faba
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - A Territo
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - J D Subiela
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - J Huguet
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - A Sánchez-Puy
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - A Gallioli
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - D Vanacore
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - A Mercade
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - C Martinez
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - J Palou
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - L Guirado
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| | - A Breda
- Departmento de Urología, Fundaciò Puigvert, Universitat Autònoma de Barcelona, Barcelona, España; Servicio de Nefrología, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, España
| |
Collapse
|
4
|
Alkassis M, Abi Tayeh G, Khalil N, Mansour R, Lilly E, Sarkis J, Moukarzel M. The safety and efficacy of Bacillus Calmette-Guerin intravesical therapy in kidney transplant recipients with superficial bladder cancer. Clin Transplant 2021; 35:e14377. [PMID: 34050983 DOI: 10.1111/ctr.14377] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2021] [Revised: 05/09/2021] [Accepted: 05/24/2021] [Indexed: 12/19/2022]
Affiliation(s)
- Marwan Alkassis
- Department of Urology, Hotel Dieu de France Hospital, University of Saint Joseph, Beirut, Lebanon
| | - Georges Abi Tayeh
- Department of Urology, Hotel Dieu de France Hospital, University of Saint Joseph, Beirut, Lebanon
| | - Nour Khalil
- Department of Urology, Hotel Dieu de France Hospital, University of Saint Joseph, Beirut, Lebanon
| | - Raymond Mansour
- Department of Urology, Hotel Dieu de France Hospital, University of Saint Joseph, Beirut, Lebanon
| | - Eddy Lilly
- Department of Urology, Hotel Dieu de France Hospital, University of Saint Joseph, Beirut, Lebanon
| | - Julien Sarkis
- Department of Urology, Hotel Dieu de France Hospital, University of Saint Joseph, Beirut, Lebanon
| | - Maroun Moukarzel
- Department of Urology, Hotel Dieu de France Hospital, University of Saint Joseph, Beirut, Lebanon
| |
Collapse
|
5
|
[Urothelial carcinoma in kidney transplant recipients and candidates: The French guidelines from CTAFU]. Prog Urol 2021; 31:31-38. [PMID: 33423744 DOI: 10.1016/j.purol.2020.04.028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 04/10/2020] [Accepted: 04/20/2020] [Indexed: 01/20/2023]
Abstract
OBJECTIVE To propose surgical recommendations for urothelial carcinoma management in kidney transplant recipients and candidates. METHOD A review of the literature (Medline) following a systematic approcah was conducted by the CTAFU regarding the epidemiology, screening, diagnosis and treatment of urothelial carcinoma in kidney transplant recipients and candidates for renal transplantation. References were assessed according to a predefined process to propose recommendations with levels of evidence. RESULTS Urothelial carcinomas occur in the renal transplant recipient population with a 3-fold increased incidence as compared with general population. While major risk factors for urothelial carcinomas are similar to those in the general population, aristolochic acid nephropathy and BK virus infection are more frequent risk factors in renal transplant recipients. As compared with general population, NMIBC in the renal transplant recipients are associated with earlier and higher recurrence rate. The safety and efficacy of adjuvant intravesical therapies have been reported in retrospective series. Treatment for localized MIBC in renal transplant recipients is based on radical cystectomy. In the candidate for a kidney transplant with a history of urothelial tumor, it is imperative to perform follow-up cystoscopies according to the recommended frequency, depending on the risk of recurrence and progression of NMIBC and to maintain this follow-up at least every six months up to transplantation whatever the level of risk of recurrence and progression. Based on current data, the present recommendations propose guidelines for waiting period before active wait-listing renal transplant candidates with a history of urothelial carcinoma. CONCLUSION The french recommendations from CTAFU should contribute to improve the management of urothelial carcinoma in renal transplant patients and renal transplant candidates by integrating both oncologic objectives and access to transplantation.
Collapse
|
6
|
Abstract
PURPOSE OF REVIEW The aim of this article is to review incidence, risk factors, and optimal management of de-novo urothelial carcinoma in transplant recipients. RECENT FINDINGS There is a two to three-fold increased risk for de-novo malignant tumors after solid-organ transplantation, but there is currently no consensus regarding optimal management of de-novo urothelial carcinoma in transplanted patients. Known risk factors include polyomavirus BK, aristolochic acid, and smoking. Data suggest a higher rate of high-grade tumors, as well as predominantly higher stage at primary diagnosis, for both NMIBC and muscle-invasive bladder cancer (MIBC). Treatment for NMIBC includes TURB, mitomycin, and Bacille de Calmette-Guérin instillation with special concern to the immunosuppressive regime. Treatment of MIBC or advanced urothelial carcinoma includes radical cystectomy with chemotherapy if the patient is eligible. A screening should be performed in all transplant recipients, to allow early diagnosis. SUMMARY De-novo urothelial carcinoma in transplant recipients is more frequent than in the general population and these tumors were more likely to be high-grade tumors and diagnosed at an advanced stage. There is very little information available on the optimal treatment for these patients. However, aggressive treatment and a strict management according the given recommendations are of the utmost importance.
Collapse
|
7
|
Yu B, Chen L, Zhang W, Li Y, Zhang Y, Gao Y, Teng X, Zou L, Wang Q, Jia H, Liu X, Zheng H, Hou P, Yu H, Sun Y, Zhang Z, Zhang P, Zhang L. TOP2A and CENPF are synergistic master regulators activated in cervical cancer. BMC Med Genomics 2020; 13:145. [PMID: 33023625 PMCID: PMC7541258 DOI: 10.1186/s12920-020-00800-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Accepted: 09/22/2020] [Indexed: 02/07/2023] Open
Abstract
Background Identification of master regulators (MRs) using transcriptome data in cervical cancer (CC) could help us to develop biomarkers and find novel drug targets to fight this disease. Methods We performed differential expression (DE) analyses of public microarray and RNA-seq transcriptome data of CC and normal cervical tissues (N). Virtual Inference of Protein activity by Enriched Regulon analysis (VIPER) was used to convert the DE outcomes to differential activity (DA) signature for MRs. Synergy analysis was conducted to study synergistic effect of MR-pairs. TCGA and microarray data were used to test the association of expression of a MR and a clinical feature or a molecular feature (e.g. somatic mutations). Various bioinformatic tools/websites (DAVID, GEPIA2, Oncomine, cBioPortal) were used to analyze the expression of the top MRs and their regulons. Results Ten DE and 10 DA signatures were generated for CC. Two MRs, DNA topoisomerase II alpha (TOP2A) and centromere protein F (CENPF) were found to be up-regulated, activated and synergistic in CC compared to N across the 10 datasets. The two MRs activate a common set of genes (regulons) with functions in cell cycle, chromosome, DNA damage etc. Higher expression of CENPF was associated with metastasis. High expression of both MRs is associated with somatic mutation of a set of genes including tumor suppressors (TP53, MSH2, RB1) and genes involved in cancer pathways, cell cycle, DNA damage and repair. The magnitude of up-regulation and the absolute expression level of both MRs in CC are significantly higher compared to many other cancer types. Conclusion TOP2A and CENPF are a synergistic pair of MRs that are overexpressed and activated in CC. Their high expression is correlated with some prognosis features (e.g. metastasis) and molecular features (e.g. somatic mutations) and distinctly high in CC vs. many other cancer types. They may be good biomarkers and anticancer drug targets for CC.
Collapse
Affiliation(s)
- Beiwei Yu
- Department of Laboratory, Hangzhou Jianggan District People's Hospital, Hangzhou, Zhejiang, China
| | - Long Chen
- Department of Gynecology, Xiao shan Hospital, Hangzhou, Zhejiang, China
| | - Weina Zhang
- Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China
| | - Yue Li
- Department of Laboratory, Jinhua People's Hospital, Jinhua, Zhejiang, China
| | - Yibiao Zhang
- Department of Laboratory, Zhejiang Jinhua Guangfu Hospital, Jinhua, Zhejiang, China
| | - Yuan Gao
- Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China
| | - Xianlin Teng
- Department of Laboratory, Jinhua People's Hospital, Jinhua, Zhejiang, China
| | - Libo Zou
- Medicine Reproductive Centre, Jinhua People's Hospital, Jinhua, Zhejiang, China
| | - Qian Wang
- Tianjia Genomes Tech CO., LTD., Hefei, Anhui, China
| | - Hongtao Jia
- Tianjia Genomes Tech CO., LTD., Hefei, Anhui, China
| | - Xiangtao Liu
- Tianjia Genomes Tech CO., LTD., Hefei, Anhui, China
| | - Hui Zheng
- Tianjia Genomes Tech CO., LTD., Hefei, Anhui, China
| | - Ping Hou
- Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China
| | - Hongyan Yu
- Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China
| | - Ying Sun
- Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China
| | - Zhiqin Zhang
- Department of Functional Discipline, School of medicine Jinhua, Jinhua, Zhejiang, China
| | - Ping Zhang
- Department of Gynecology, Qingdao Municipal Hospital, Qingdao, Shandong, China
| | - Liqin Zhang
- Department of Laboratory, Hangzhou Jianggan District People's Hospital, Hangzhou, Zhejiang, China. .,Department of Laboratory, Jinhua People's Hospital, Jinhua, Zhejiang, China.
| |
Collapse
|
8
|
Pelvic Surgery in the Transplant Recipient: Important Considerations for the Non-transplant Surgeon. Curr Urol Rep 2020; 21:2. [PMID: 31960158 DOI: 10.1007/s11934-020-0954-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
PURPOSE OF REVIEW Classically, kidney transplantation (KT) consists of heterotopic implantation of the renal graft in the iliac fossa with vascular anastomosis on the iliac vessel and reimplantation of the graft ureter in the bladder of the recipient. However, a wide range of variations exist in both vascular anastomosis and urinary diversion that the non-transplant surgeon should know. RECENT FINDINGS For any pelvic surgery in a KT patient, the non-transplant surgeon should preoperatively evaluate the anatomy of the graft, its vascularization and its urinary tract. The transplant ureter should be identified and secured by preoperative JJ stenting whenever needed. For any surgery, maintenance and control of both immunosuppressive treatment and renal function is crucial. The advice or even the assistance of a transplant surgeon should be required because any damage to vascularization or urinary drainage of the renal graft could have dramatic and definitive consequences on graft function.
Collapse
|
9
|
Melittin Constrains the Expression of Identified Key Genes Associated with Bladder Cancer. J Immunol Res 2018; 2018:5038172. [PMID: 29854840 PMCID: PMC5960535 DOI: 10.1155/2018/5038172] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 03/02/2018] [Accepted: 04/02/2018] [Indexed: 12/25/2022] Open
Abstract
This work is aimed at investigating the effect of melittin on identified key genes in bladder cancer (BC) and further providing a theoretical basis for BC treatment. GSE35014 downloaded from the Gene Expression Omnibus (GEO) database was used to screen differentially expressed genes (DEGs) in BC cells and control. Results showed that a total of 389 upregulated and 169 downregulated genes were identified. Subsequently, GO analysis, KEGG pathway enrichment analysis, and PPI network analysis were employed to disclose the crucial genes and signaling pathways involved in BC. Fifteen module-related DEGs and their associated signaling pathways were obtained according to the PPI network and modular analyses. Based on the analysis of articles retrieved in the PubMed database, we found that melittin could induce apoptosis and constrain the progression of tumor cells as a result of regulating critical cancer-related signaling pathways, such as PI3K-Akt and TNF signaling pathways. Furthermore, PI3K-Akt and TNF signaling pathways were also found to be associated with module-related DEGs according to biological analyses. At last, qRT-PCR analysis demonstrated that melittin could constrain the expression of module-related DEGs (LPAR1, COL5A1, COL6A2, CXCL1, CXCL2, and CXCL3) associated with PI3K-Akt and TNF signaling pathways in BC cells. Functional assays revealed that melittin could constrain the proliferative and migrated abilities of BC cells. Conjointly, these findings provide a theoretical basis for these six genes as drug-sensitive markers of melittin in BC treatment.
Collapse
|